Previous Frame Next Frame
  • Discover: How Intrexon
    is creating the code for a
    healthier planet

    World Demand
  • Intrexon Energy Partners to
    Generate High-value Oil Products
    from Low-Cost Natural Gas

    DISCOVER

    Intrexon Energy Partners to Generate High-value Oil Products from Low-Cost Natural Gas
  • Optimizing therapeutics production:
    Improving the way we generate active pharmaceutical ingredients

    DISCOVER

    Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Intrexon and Johnson & Johnson to
    advance new hair and skin products

    DISCOVER

    Johnson & Johnson Innovation
  • Next-generation fertility solutions

    DISCOVER

    OvaScience
  • World Demand
  • Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Johnson & Johnson Innovation
  • OvaScience

UltraVector® platform to power the next generation of bio-based products
LEAP® automated purification of high value cells
RheoSwitch® precisely controlled expression
IN THE SPOTLIGHT
HEALTH
Collaboration:
Ziopharm and Intrexon are on the path to treating melanoma
FOOD
Extreme Weather:
Drought and the need for novel food applications
ENERGY
Engineering Energy:
Fueling the world with microbes
LATEST NEWS
Intrexon Announces Third Quarter 2014 Financial Results
GERMANTOWN, Md., Nov. 13, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its third quarter results for 2014.  Business Highlights and Recent Developments: Closed the acquisition of Trans Ova Genetics, L.C. ("Trans Ova"), an industry-leading provider of bovine reproductive technologies and the largest producer and supplier of bovine embryos in North America. The combined tools and expertise of Intrexon and Trans Ova should enable the companies to accelerate efficiency in related food and protein production.  Established an Exclusive Channel Collaboration with Sanofi Chimie, a wholly owned subsidiary of Sanofi, to develop an e...
Study Demonstrates Automated Laser-based Cell Manipulation with Intrexon's Proprietary LEAP® System
GERMANTOWN, Md., Nov. 6, 2014 /PRNewswire/ -- A new study by scientists at Sanford-Burnham Medical Research Institute, a nonprofit research institution and one of the largest induced pluripotent stem cell (iPSC) generators in the world, in collaboration with Intrexon Corporation (NYSE: XON) a leader in synthetic biology, describes an automated, efficient procedure for generating human iPSCs with the Laser Enabled Analysis and Processing (LEAP®) system.  The protocol "Laser-Assisted Generation of Human Induced Pluripotent Stem Cells", published online in Current Protocols in Stem Cell Biology, has implications in the advancement of iPSC research.   Intrexon's proprietary LEAP® system int...
Intrexon to Announce Third Quarter 2014 Results and Host Conference Call on November 13th
GERMANTOWN, Md., Nov. 6, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) today announced it will release third quarter 2014 financial results after the market closes on Thursday, November 13th, 2014.  The Company will host a conference call at 5:30 PM ET to discuss the results and provide a general business update. The conference call may be accessed by dialing 1-888-346-3959 (Domestic US) and 1-412-902-4262 (International) and asking to join the "Intrexon Conference Call."  Participants may also access the live webcast through Intrexon's website in the Investors section under Calendar of Events. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthe...